Combination of Janus kinase inhibitor and biologic for recalcitrant severe atopic dermatitis
Open Access
- 29 May 2024
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (1) , e94-e97
Abstract
No abstract availableFunding Information
- Fonds De La Recherche Scientifique - FNRS (1M00524F)
This publication has 6 references indexed in Scilit:
- Is the treat‐retreat strategy a viable option for atopic dermatitis patients undergoing Janus kinase inhibitor treatment? A report on two successful cases with upadacitinibJournal of the European Academy of Dermatology and Venereology, 2023
- JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patientsJAAD Case Reports, 2023
- Dupilumab with concomitant Janus kinase inhibitor: a novel treatment strategy for atopic dermatitis with poor response to dupilumabBritish Journal of Dermatology, 2022
- The New Era of Biologics in Atopic Dermatitis: A ReviewDermatology Practical & Conceptual, 2021
- Current and future status of JAK inhibitorsThe Lancet, 2021
- Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapyJAAD Case Reports, 2021